Description
Cholinergic Drugs for Alzheimer's Disease: From Central Cholinergic Neurotransmission to Drug Therapies and Natural Products with Multitarget Actions addresses the urgent need for advanced resources in neuropharmacology. The first section presents mechanistic insights into cholinergic drugs, current hypotheses for Alzheimer's Disease progression, neurotransmitter systems, receptor biology, and the evolution of acetylcholinesterase inhibitors, including hybrid and multi-target drugs. It also covers clinical status, neuromuscular blockers, non-adrenergic neurotransmitters, protein kinase inhibitors, inflammation modulation, NMDA antagonism, biomarkers, and AI-assisted drug discovery.The second section explores natural alkaloidal and non-alkaloidal compounds, molecular docking, SAR analysis, and daily consumable resources, with the third section investigating marine-derived AChE inhibitors, dual- and multi-target drug concepts, and emerging therapeutic compounds. This book equips the scientific community with a robust foundation for understanding and innovating in Alzheimer's Disease therapy. By integrating molecular biology, pharmacology, and computational approaches, it empowers researchers and clinicians to address treatment challenges, optimize drug design, and leverage natural products for multifactorial intervention.- Explores cholinesterase inhibitors for cognitive improvement- Summarizes receptor mechanisms in cholinergic transmission- Reviews marine and plant-derived AChE inhibitors for innovative treatments- Presents emerging drug therapies and multitarget natural compounds for Alzheimer's Disease
Table of Contents
Section 1. Cholinergic drugs for Alzheimer's disease: Mechanisms, emerging and future evolution1. Introduction2. Current hypothesis for AD progression3. Neurotransmitter (NT) systems and peripheral nerve system (PNS)4. ACh receptors in ACh transmission5. Choline esterase6. Cholinergic ACh, AChE, and its inhibitors7. Classification of ChE inhibitors by binding mode8. Classification of ChE inhibitors by action mechanism9. Clinical status of ChE inhibitors10. AChE inhibitors11. Forthcoming generation of AChE inhibitors12. Hybrid inhibitors13. AChR-targeted drugs for AD treatment13.1 mAChR muscarinic receptors and antagonists 15413.2 Semisynthetic and synthetic congeners of ACh antagonists 156References 15814. Cholinergic neuromuscular junction and its blocking agents (blockers)15. Nonadrenergic and noncholinergic (NANC) NTs16. Protein kinase inhibitors for treatment of AD17. Inhibition of cholinergic inflammation via AChE inhibitor interaction with α4β2 nAChR and α7nAChR, not AChE enzyme inhibition18. NMDA and non-NMDA receptor antagonism for ADmtreatment19. Challenges in recent AD therapeutic approaches20. Identification and application of biomarkers for AD21 Artificial intelligence (AI)-assisted AD target and drugdiscovery22. Conclusion and perspectivesSection 2. Natural alkaloidal and non-alkaloidal anti-AChE and anti- Alzheimer's disease compounds in the symptomatic intimation of Alzheimer's disease23. Introduction24. Current bioactive molecules in Alzheimer's disease therapy25. Emerging lead compounds from naturally occurring molecules for Alzheimer's disease therapy26. Natural antiAChE compounds for Alzheimer's disease therapy27. Molecular docking simulation for consistency between SAR results and in vitro AChE inhibitory activities28. Conceptual search for MTDs of plant natural compounds for multifactorial Alzheimer's disease therapy29. AChE inhibitors in daily consumable cereals and food resources30. Conclusion and perspectiveSection 3. Marine AChE inhibitors for the symptomatic treatment of Alzheimer's disease31. Introduction32. Localization, structure and cellular function of AChE33. AChE inhibitors from marine resources34. Non-ChE inhibitory anti-Alzheimer's disease compounds35. Emerging concept of dual-target drug (DTD) and multitarget drug (MTD) in AD pathology and promising AD drugs36. Conclusion and prospectivesIndex
